These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25534238)

  • 21. Targeted Therapies for the Treatment of Glioblastoma in Adults.
    Chuang DF; Lin X
    Curr Oncol Rep; 2019 May; 21(7):61. PubMed ID: 31102038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
    Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
    Schaub C; Schäfer N; Mack F; Stuplich M; Kebir S; Niessen M; Tzaridis T; Banat M; Vatter H; Waha A; Herrlinger U; Glas M
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1825-9. PubMed ID: 27318492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current State of Immunotherapy for Treatment of Glioblastoma.
    McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
    Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
    Batich KA; Sampson JH
    Expert Opin Pharmacother; 2014 Oct; 15(14):2047-61. PubMed ID: 25139628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Alexander BM; Ba S; Berger MS; Berry DA; Cavenee WK; Chang SM; Cloughesy TF; Jiang T; Khasraw M; Li W; Mittman R; Poste GH; Wen PY; Yung WKA; Barker AD;
    Clin Cancer Res; 2018 Feb; 24(4):737-743. PubMed ID: 28814435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.
    Roy LO; Poirier MB; Fortin D
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
    Gorlia T; Stupp R; Brandes AA; Rampling RR; Fumoleau P; Dittrich C; Campone MM; Twelves CC; Raymond E; Hegi ME; Lacombe D; van den Bent MJ
    Eur J Cancer; 2012 May; 48(8):1176-84. PubMed ID: 22464345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
    Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
    J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.